Karyopharm Therapeutics Inc. (KPTI) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
KPTI has been the topic of several other reports. Vetr lowered shares of Karyopharm Therapeutics from a strong-buy rating to a buy rating and set a $11.00 target price on the stock. in a research note on Wednesday, August 31st. Leerink Swann reissued an outperform rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, October 7th. S&P Equity Research lowered their price objective on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a report on Tuesday, August 30th. Jefferies Group upgraded shares of Karyopharm Therapeutics from a hold rating to a buy rating and upped their price objective for the stock from $9.00 to $12.00 in a report on Tuesday, August 30th. Finally, Wedbush restated an outperform rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $15.47.
Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.91 on Friday. Karyopharm Therapeutics has a 12 month low of $4.83 and a 12 month high of $19.41. The stock has a 50 day moving average of $8.72 and a 200-day moving average of $8.34. The company’s market cap is $408.72 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. Equities research analysts expect that Karyopharm Therapeutics will post ($3.00) EPS for the current year.
WARNING: This article was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/28/karyopharm-therapeutics-inc-kpti-lowered-to-hold-at-zacks-investment-research.html.
In other Karyopharm Therapeutics news, insider Ran Frenkel sold 3,309 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $10.06, for a total transaction of $33,288.54. Following the completion of the transaction, the insider now owns 14,691 shares in the company, valued at $147,791.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.79% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its position in Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock worth $11,323,000 after buying an additional 1,096,029 shares during the period. Baker BROS. Advisors LP purchased a new position in Karyopharm Therapeutics during the third quarter worth approximately $2,111,000. New Leaf Venture Partners L.L.C. raised its position in Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares during the period. Vanguard Group Inc. raised its position in Karyopharm Therapeutics by 18.5% in the second quarter. Vanguard Group Inc. now owns 816,444 shares of the company’s stock worth $5,478,000 after buying an additional 127,714 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its position in Karyopharm Therapeutics by 68.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the company’s stock worth $2,627,000 after buying an additional 110,000 shares during the period. Institutional investors own 56.26% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.